Abirateronacetat CAS:154229-18-2

Androgenantagonister.Abirateronacetat (VÄRDSHUS, USAN, FÖRBJUDA, JAN) (varumärken Zytiga, Abirate, Abretone, Abirapro) är en steroid antiandrogen, specifikt en androgensynteshämmare, används i kombination med vid metastaserad kastrationsresistent prostatacancer (tidigare kallad hormonresistent eller hormonrefraktär prostatacancer) – dvs., prostatacancer som inte svarar på androgenbrist eller behandling med androgenreceptorantagonister. It is a prodrug to the active agent abiraterone, and is marketed by Janssen Biotech under the trade name Zytiga. För övrigt, Intas Pharmaceuticals markets the drug under the trade name Abiratas, Cadila Pharmaceuticals markets the drug as Abretone, and Glenmark Pharmaceuticals as Abirapro.

Abiraterone acetate was approved by the United States Food and Drug Administration on April 28, 2011. The FDA press release made reference to a phase III clinical trial in which abiraterone use was associated with a median survival of 14.8 months versus 10.9 months with placebo; the study was stopped early because of the successful outcome.

Use in Cancer Abiraterone acetate is approved to be used with to treat Prostate cancer that has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other hormone therapy.Abiraterone is also being studied in the treatment of other types of cancer.